ADIPOQ and type 2 diabetes mellitus: The fact that p-F11 exhibits partial efficacy in activating PPARγ, but increases adiponectin secretion and inhibits obesity-linked phosphorylation of PPARγ, makes it a potential therapeutic agent for the treatment of type 2 diabetes.